123 related articles for article (PubMed ID: 23939154)
1. [Pathological and immunohistochemical analyses of 32 cases of nephrogenic adenoma].
Shen Q; Sun LH; Wang JH; Liu LB; He Q; Jin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Aug; 45(4):522-6. PubMed ID: 23939154
[TBL] [Abstract][Full Text] [Related]
2. Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma.
Skinnider BF; Oliva E; Young RH; Amin MB
Am J Surg Pathol; 2004 Jun; 28(6):701-5. PubMed ID: 15166661
[TBL] [Abstract][Full Text] [Related]
3. Flat pattern of nephrogenic adenoma: previously unrecognized pattern unveiled using PAX2 and PAX8 immunohistochemistry.
Piña-Oviedo S; Shen SS; Truong LD; Ayala AG; Ro JY
Mod Pathol; 2013 Jun; 26(6):792-8. PubMed ID: 23328975
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical markers for the differential diagnosis of nephrogenic adenomas.
Quinones W; Ziober A; Yao Y; Bing Z
Ann Diagn Pathol; 2013 Feb; 17(1):41-4. PubMed ID: 22672805
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the immunophenotype of nephrogenic adenoma.
Fromont G; Barcat L; Gaudin J; Irani J
Am J Surg Pathol; 2009 Nov; 33(11):1654-8. PubMed ID: 19730362
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological features and differential diagnosis of metanephric adenoma: a report of sixteen cases].
Xi CG; Fan Y; Yang XY; Liu LB; Wang JH; Hu S; Li YY; He Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):598-602. PubMed ID: 29263496
[TBL] [Abstract][Full Text] [Related]
7. Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma.
Gupta A; Wang HL; Policarpio-Nicolas ML; Tretiakova MS; Papavero V; Pins MR; Jiang Z; Humphrey PA; Cheng L; Yang XJ
Am J Surg Pathol; 2004 Sep; 28(9):1224-9. PubMed ID: 15316323
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Xiao GQ; Burstein DE; Miller LK; Unger PD
Arch Pathol Lab Med; 2006 Jun; 130(6):805-10. PubMed ID: 16740031
[TBL] [Abstract][Full Text] [Related]
9. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic adenoma: an immunohistochemical analysis using biotin-free methods.
Ortiz-Rey JA; Antón-Badiola I; Pérez-Pedrosa A; Peteiro-Cancelo Á; González-Carreró J
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):386-91. PubMed ID: 22495376
[TBL] [Abstract][Full Text] [Related]
11. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic adenoma of the urinary tract: A 6-year single center experience.
Turcan D; Acikalin MF; Yilmaz E; Canaz F; Arik D
Pathol Res Pract; 2017 Jul; 213(7):831-835. PubMed ID: 28554748
[TBL] [Abstract][Full Text] [Related]
13. Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Sun K; Huan Y; Unger PD
Arch Pathol Lab Med; 2008 Sep; 132(9):1417-22. PubMed ID: 18788852
[TBL] [Abstract][Full Text] [Related]
14. Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Olgac S; Hutchinson B; Tickoo SK; Reuter VE
Mod Pathol; 2006 Feb; 19(2):218-24. PubMed ID: 16424894
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3.
McDaniel AS; Chinnaiyan AM; Siddiqui J; McKenney JK; Mehra R
Am J Surg Pathol; 2014 Dec; 38(12):1664-71. PubMed ID: 24921643
[TBL] [Abstract][Full Text] [Related]
16. Nephrogenic adenoma of the urinary tract: a review.
Alexiev BA; LeVea CM
Int J Surg Pathol; 2012 Apr; 20(2):123-31. PubMed ID: 22415059
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
18. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic Adenoma of the Prostatic Urethra Mimicking Prostatic and Bladder Carcinomas.
Beeter MC; Fazili T; Yeh YA
Cureus; 2023 Mar; 15(3):e35998. PubMed ID: 37041930
[TBL] [Abstract][Full Text] [Related]
20. Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy.
Dalfior D; Delahunt B; Brunelli M; Parisi A; Ficarra V; Novara G; Novella G; Gobbo S; Valotto C; Chilosi M; Menestrina F; Martignoni G
Pathology; 2010 Jan; 42(1):1-5. PubMed ID: 20025473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
